The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics

Naviglio, 1998, UBPY: a growth-regulated human ubiquitin isopeptidase, EMBO J., 17, 3241, 10.1093/emboj/17.12.3241 Clague, 2006, Endocytosis: the DUB version, Trends Cell Biol., 16, 551, 10.1016/j.tcb.2006.09.002 Wright, 2011, Regulation of endocytic sorting by ESCRT-DUB-mediated deubiquitination, Cell Biochem. Biophys., 60, 39, 10.1007/s12013-011-9181-9 Komada, 2018, USP8 (Ubiquitin-Specific protease 8), 5855 Komada, 2008, Controlling receptor downregulation by ubiquitination and deubiquitination, Curr. Drug Discov. Technol., 5, 78, 10.2174/157016308783769469 Mizuno, 2007, 14-3-3-dependent inhibition of the deubiquitinating activity of UBPY and its cancellation in the M phase, Exp. Cell Res., 313, 3624, 10.1016/j.yexcr.2007.07.028 Komada, 2015, Mutations in the deubiquitinase gene USP8 cause Cushing's disease, Nat. Genet., 47, 31, 10.1038/ng.3166 D'Angelo, 2019, Emerging role of USP8, HMGA, and non-coding RNAs in pituitary tumorigenesis, Cancers, 11, 1302, 10.3390/cancers11091302 Perez-Rivas, 2015, The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushing's disease, J. Clin. Endocrinol. Metab., 100, E997, 10.1210/jc.2015-1453 Ma, 2015, Recurrent gain-of-function USP8 mutations in Cushing's disease, Cell Res., 25, 306, 10.1038/cr.2015.20 Callis, 2014, The ubiquitination machinery of the ubiquitin system, Arabia B., 12 Lecker, 2006, Protein degradation by the ubiquitin-proteasome pathway in normal and disease states, J. Am. Soc. Nephrol., 17, 1807, 10.1681/ASN.2006010083 Amerik, 2004, Mechanism and function of deubiquitinating enzymes, Biochim. Biophys. Acta Mol. Cell Res., 1695, 189, 10.1016/j.bbamcr.2004.10.003 Durcan, 2014, USP 8 regulates mitophagy by removing K 6‐linked ubiquitin conjugates from parkin, EMBO J., 33, 2473, 10.15252/embj.201489729 Sun, 2018, The ubiquitin-specific protease USP8 deubiquitinates and stabilizes Cx43, J. Biol. Chem., 293, 8275, 10.1074/jbc.RA117.001315 Siegel, 2019, Cancer statistics, CA A Cancer J. Clin., 69, 7, 10.3322/caac.21551 Tanizaki, 2011, Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification, Br. J. Canc., 105, 807, 10.1038/bjc.2011.322 Maulik, 2003, Role of receptor tyrosine kinases in lung cancer, Methods Mol. Med., 74, 113 Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer, J. Clin. Oncol., 21, 2237, 10.1200/JCO.2003.10.038 Rowinsky, 2004, Artic. J. Clin. Oncol., 22, 3238, 10.1200/JCO.2004.11.057 Jackman, 2010, Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer, J. Clin. Oncol., 28, 357, 10.1200/JCO.2009.24.7049 Harrison, 2020, Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, Semin. Canc. Biol., 61, 167, 10.1016/j.semcancer.2019.09.015 Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, journals, Plos.Org, 2, 225 Byun, 2013, USP8 is a novel target for overcoming gefitinib resistance in lung cancer, Clin. Canc. Res., 19, 3894, 10.1158/1078-0432.CCR-12-3696 Lee, 2018, Phase I trial of anti-MET monoclonal antibody in MET-overexpressed refractory cancer, Clin. Colorectal Canc., 17, 140, 10.1016/j.clcc.2018.01.005 Lee, 2014, Cbl-independent degradation of Met: ways to avoid agonism of bivalent met-targeting antibody, Oncogene, 33, 34, 10.1038/onc.2012.551 Oh, 2014, USP8 modulates ubiquitination of LRIG1 for Met degradation, Sci. Rep., 4, 4980, 10.1038/srep04980 Baloch, 2017, Knowledge and awareness of cervical cancer, human papillomavirus (HPV), and HPV vaccine among HPV-infected Chinese women, Med. Sci. Mon. Int. Med. J. Exp. Clin. Res., 23, 4269 Yan, 2018, High expression of ubiquitin-specific protease 8 (USP8) is associated with poor prognosis in patients with cervical squamous cell carcinoma, Med. Sci. Mon. Int. Med. J. Exp. Clin. Res., 24, 4934 Jeong, 2017, USP8 suppresses death receptor-mediated apoptosis by enhancing FLIP L stability, Oncogene, 36, 458, 10.1038/onc.2016.215 Rizvi, 2018, Cholangiocarcinoma-evolving concepts and therapeutic strategies, Nat. Rev. Clin. Oncol., 15, 95, 10.1038/nrclinonc.2017.157 Jing, 2020, Down-regulation of usp8 inhibits cholangiocarcinoma cell proliferation and invasion, Canc. Manag. Res., 12, 2185 Sáez, 2003, Plasma membrane channels formed by connexins: their regulation and functions, Physiol. Rev., 83, 1359, 10.1152/physrev.00007.2003 Giepmans, 2001, Interaction of c-Src with gap junction protein connexin-43. Role in the regulation of cell-cell communication, J. Biol. Chem., 276, 8544, 10.1074/jbc.M005847200 Aasen, 2016, Gap junctions and cancer: communicating for 50 years, Nat. Rev. Canc., 16, 775, 10.1038/nrc.2016.105 Grek, 2016, Connexin 43, breast cancer tumor suppressor: missed connections?, Canc. Lett., 374, 117, 10.1016/j.canlet.2016.02.008 Gridley, 2007, Notch signaling in vascular development and physiology, Development, 134, 2709, 10.1242/dev.004184 Li, 2017, Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy, Med. Oncol., 34, 1, 10.1007/s12032-017-1039-6 Shin, 2020, Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer, Cell Death Differ., 27, 1341, 10.1038/s41418-019-0419-1 Berlin, 2010, Regulation of epidermal growth factor receptor ubiquitination and trafficking by the USP8·STAM complex, J. Biol. Chem., 285, 34909, 10.1074/jbc.M109.016287 Mizuno, 2005, Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes, Mol. Biol. Cell, 16, 5163, 10.1091/mbc.e05-06-0560 Qiu, 2018, The expression of ubiquitin-specific peptidase 8 and its prognostic role in patients with breast cancer, J. Cell. Biochem., 119, 10051, 10.1002/jcb.27337 Asa, 2017, From pituitary adenoma to pituitary neuroendocrine tumor (pitnet): an international pituitary pathology club proposal, Endocr. Relat. Canc., 24, C5, 10.1530/ERC-17-0004 Trouillas, 2014, In search of a prognostic classification of endocrine pituitary tumors, Endocr. Pathol., 25, 124, 10.1007/s12022-014-9322-y Hayashi, 2016, The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease, Eur. J. Endocrinol., 174, 213, 10.1530/EJE-15-0689 Losa, 2019, Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas, Endocrine, 63, 240, 10.1007/s12020-018-1776-0 Fukuoka, 2011, EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas, J. Clin. Invest., 121, 4712, 10.1172/JCI60417 Chen, 2009, Emerging roles of E2Fs in cancer: an exit from cell cycle control, Nat. Rev. Canc., 9, 785, 10.1038/nrc2696 Alla, 2010, E2F1 in melanoma progression and metastasis, J. Natl. Cancer Inst., 102, 127, 10.1093/jnci/djp458 Araki, 2017, EGFR induces E2F1-mediated corticotroph tumorigenesis, J. Endocr. Soc., 1, 127, 10.1210/js.2016-1053 Araki, 2016, E2F1-mediated human POMC expression in ectopic Cushing's syndrome, Endocr. Relat. Canc., 23, 857, 10.1530/ERC-16-0206 Wang, 2015, POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation, Nat. Commun., 6, 8704, 10.1038/ncomms9704 Castellnou, 2020, Sst5 expression and usp8 mutation in functioning and silent corticotroph pituitary tumors, Endocr. Connect., 9, 243, 10.1530/EC-20-0035 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA, Cancer J. Clin., 68, 394, 10.3322/caac.21492 Wang, 2014, The role of HER3 in gastric cancer, Biomed, Pharma, 68, 809 Sun, 2020, Down-regulation of usp8 suppresses her-3 positive gastric cancer cells proliferation, OncoTargets Ther., 13, 7973, 10.2147/OTT.S264108 Huang, 2020, Rab43 promotes gastric cancer cell proliferation and metastasis via regulating the pi3k/akt signaling pathway, OncoTargets Ther., 13, 2193, 10.2147/OTT.S237356 Mayer, 2016, The PI3K/AKT pathway as a target for cancer treatment, Annu. Rev. Med., 67, 11, 10.1146/annurev-med-062913-051343 Bao, 2010, HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion, Arch. Biochem. Biophys., 499, 49, 10.1016/j.abb.2010.05.009 Harrigan, 2018, Deubiquitylating enzymes and drug discovery: emerging opportunities, Nat. Rev. Drug Discov., 17, 57, 10.1038/nrd.2017.152 Fraile, 2012, Deubiquitinases in cancer: new functions and therapeutic options, Oncogene, 31, 2373, 10.1038/onc.2011.443 Kaushal, 2018, Deubiquitinating enzymes in cancer stem cells: functions and targeted inhibition for cancer therapy, Drug Discov. Today, 23, 10.1016/j.drudis.2018.05.035 Yu, 2008, FLIP and the death effector domain family, Oncogene, 27, 6216, 10.1038/onc.2008.299 Dickens, 2012, A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death, Mol. Cell., 47, 291, 10.1016/j.molcel.2012.05.004 Porta, 2014, Targeting PI3K/Akt/mTOR signaling in cancer, Front. Oncol., 10.3389/fonc.2014.00064 Shariati, 2019, Targeting AKT for cancer therapy, Expet Opin. Invest. Drugs, 28, 977, 10.1080/13543784.2019.1676726 Sigismund, 2018, Emerging functions of the EGFR in cancer, Mol. Oncol., 12, 3, 10.1002/1878-0261.12155 Kim, 2017, Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma, Pathol. Int., 67, 292, 10.1111/pin.12546 Montanari, 2017, Epithelial-mesenchymal transition in prostate cancer: an overview, Oncotarget, 8, 35376, 10.18632/oncotarget.15686 Grille, 2003, The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines, Canc. Res., 63, 2172 Gold, 2013, A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC), J. Clin. Oncol., 31, 10.1200/jco.2013.31.15_suppl.8104 Xie, 2013, Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo, Eur. J. Canc., 49, 3559, 10.1016/j.ejca.2013.07.007 Yerbes, 2012, Control of FLIPL expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells, Cell Death Differ., 19, 10.1038/cdd.2012.78 Islam, 2019, Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics, Cell Biochem. Funct., 37, 304, 10.1002/cbf.3401 Colombo, 2010, Synthesis and biological evaluation of 9-oxo-9 H -indeno[1,2- b ]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes, ChemMedChem, 5, 552, 10.1002/cmdc.200900409 Anees, 2011, Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression, Cancer, 117, 1172, 10.1002/cncr.25504